Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI; Marianne Brodmann, MD; Keith Sterling, MD
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
In this video interview, a patient who had been told they were out of options for limb salvage describes traveling from New York City to the Boston area to pursue a new limb-sparing procedure not otherwise available to them.
In this video interview, a patient who had been told they were out of options for limb salvage describes traveling from New York City to the Boston area to pursue a new limb-sparing procedure not otherwise available to them.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Three late-breaking VIVA26 studies reported new data on bleeding risk with ultrasound-facilitated catheter-directed thrombolysis, wearable-based functional recovery after intermediate-high-risk PE, and Laguna Thrombectomy System™ safety and...
Three late-breaking VIVA26 studies reported new data on bleeding risk with ultrasound-facilitated catheter-directed thrombolysis, wearable-based functional recovery after intermediate-high-risk PE, and Laguna Thrombectomy System™ safety and...
Six late-breaking VIVA26 studies reported new data on sirolimus-based balloon and resorbable scaffold therapies, as well as adjunctive pharmacologic treatment, for patients with PAD and chronic limb-threatening ischemia.
Six late-breaking VIVA26 studies reported new data on sirolimus-based balloon and resorbable scaffold therapies, as well as adjunctive pharmacologic treatment, for patients with PAD and chronic limb-threatening ischemia.
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
